In a multi-centre randomised controlled trial (RCT), we are assessing whether giving very preterm (i.e., born at < 32 weeks’ gestation) infants prophylactic enteral bovine lactoferrin supplementation (150 mg/kg/day) from shortly after birth until 34 weeks’ post-menstrual age reduces the incidence of late-onset invasive infection (primary outcome), all-cause mortality, bronchopulmonary dysplasia, necrotising enterocolitis, retinopathy of prematurity, and the duration of antibiotic exposure, intensive care, and hospital admission. The trial is recruiting 2,200 participants from 37 neonatal care centres in the UK over 4 years. We will undertake an economic evaluation within the RCT to evaluate cost-effectiveness and provide an estimate of incremental costs for differences in the pre-specified outcomes in primary and subgroup analyses. If a statistically significant and clinically important effect on the primary outcome is detected, we will seek further funding and approval to assess the impact of enteral lactoferrin supplementation on rates of adverse neuro-developmental outcomes in the participating infants when they are 5 years old.

Keywords:
Preterm infants, Lactoferrin, Infection
1.
Vergnano S, Menson E, Kennea N, Embleton N, Russell AB, Watts T, et al: Neonatal infections in England: the NeonIN surveillance network. Arch Dis Child Fetal Neonatal Ed 2011; 96:F9–F14.
2.
Shane AL, Sánchez PJ, Stoll BJ: Neonatal sepsis. Lancet 2017; 390: 1770–1780.
3.
Bassler D, Stoll BJ, Schmidt B, Asztalos EV, Roberts RS, Robertson CM, et al: Using a count of neonatal morbidities to predict poor outcome in extremely low birth weight infants: added role of neonatal infection. Pediatrics 2009; 123: 313–318.
4.
Embleton ND, Berrington JE, McGuire W, Stewart CJ, Cummings SP: Lactoferrin: antimicrobial activity and therapeutic potential. Semin Fetal Neonatal Med 2013; 18: 143–149.
5.
Ochoa TJ, Cleary TG: Effect of lactoferrin on enteric pathogens. Biochimie 2009; 91: 30–34.
6.
Valenti P, Antonini G: Lactoferrin: an important host defence against microbial and viral attack. Cell Mol Life Sci 2005; 62: 2576–2587.
7.
Legrand D, Pierce A, Elass E, Carpentier M, Mariller C, Mazurier J: Lactoferrin structure and functions. Adv Exp Med Biol 2008; 606: 163–194.
8.
González-Chávez SA, Arévalo-Gallegos S, Rascón-Cruz Q: Lactoferrin: structure, function and applications. Int J Antimicrob Agents 2009; 33: 301.e1–e8.
9.
Tian H, Maddox IS, Ferguson LR, Shu Q: Influence of bovine lactoferrin on selected probiotic bacteria and intestinal pathogens. Biometals 2010; 23: 593–596.
10.
Actor JK, Hwang SA, Kruzel ML: Lactoferrin as an immune modulator. Curr Pharm Des 2009; 15: 1956–1973.
11.
Buccigrossi V, de Marco G, Bruzzese E, Ombrato L, Bracale I, Polito G, et al: Lactoferrin induces concentration-dependent functional modulation of intestinal proliferation and differentiation. Pediatr Res 2007; 61: 410–414.
12.
Raghuveer TS, McGuire EM, Martin SM, Wagner BA, Rebouché CJ, Buettner GR, et al: Lactoferrin in the preterm infants’ diet attenuates iron-induced oxidation products. Pediatr Res.2002; 52: 964–972.
13.
Vorland LH, Ulvatne H, Andersen J, Haukland H, Rekdal O, Svendsen JS, et al: Lactoferricin of bovine origin is more active than lactoferricins of human, murine and caprine origin. Scand J Infect Dis 1998; 30: 513–517.
14.
Yamauchi K, Toida T, Nishimura S, Nagano E, Kusuoka O, Teraguchi S, et al: 13-Week oral repeated administration toxicity study of bovine lactoferrin in rats. Food Chem Toxicol 2000; 38: 503–512.
15.
Pammi M, Suresh G: Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2017; 6: CD007137.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.